3-amino-5-piperidin-1-ylmethyl-oxazolidin-2-one | 92098-89-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 3-amino-5-piperidin-1-ylmethyl-oxazolidin-2-one
• 英文别名: 3-amino-5-piperidinomethyl-oxazolidin-2-one；3-Amino-5-piperidinomethyl-oxazolidin-2-on；3-Amino-5-(piperidinomethyl)-2-oxazolidinon；3-Amino-5-(1-piperidinyl)methyl-2-oxazolidinone；3-amino-5-(piperidin-1-ylmethyl)-1,3-oxazolidin-2-one
• CAS: 92098-89-0
• 化学式: C₉H₁₇N₃O₂
• 分子量: 199.253
• InChiKey: PFACHNUTGNRQSL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  58.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-amino-5-piperidin-1-ylmethyl-oxazolidin-2-one 、 1-甲基-5-硝基-1H-咪唑-2-甲醛 在 盐酸 作用下， 以 乙醇 为溶剂， 生成 3-(1-methyl-5-nitro-1H-imidazol-2-ylmethyleneamino)-5-piperidin-1-ylmethyl-oxazolidin-2-one
  参考文献：
  名称：

  化学治疗硝基杂环。6.取代5-氨基甲基-3-（5-硝基-2-咪唑基亚甲基氨基）-2-恶唑烷酮。

  摘要：

  DOI：

  10.1021/jm00284a003
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 一水合肼 作用下， 生成 3-amino-5-piperidin-1-ylmethyl-oxazolidin-2-one
  参考文献：
  名称：

  Series of new nu-(5-nitro-2-furyl) alkylidene-3-amino-5-tertiaryaminomethyl-2-oxazolidones and salts thereof

  摘要：

  公开号：

  US02798068A1

文献信息

• Cyclic urethanes useful as antiarrhythmic and antifibrillatory agents
  申请人：The Procter & Gamble Company

  公开号：US05994354A1

  公开（公告）日：1999-11-30

  The novel cyclic urethanes, and their pharmaceutically-acceptable salts and esters, described herein which are useful as antiarrhythmic and antifibrillatory agents and have the following general structure: ##STR1## wherein (a) X is a saturated or unsaturated, 5-, 6-, or 7-membered heterocycle or carbocycle; (b) Y is a substituted or unsubstituted, saturated or unsaturated, 5-, 6-, or 7-membered heterocyclic ring or carbocyclic ring, or is nil; (c) L is selected from the group consisting of alkylamino, alkenylamino, alkylimino, alkenylimino and acylamino; wherein the nitrogen atom thereof is bound to the nitrogen atom at the 3-position of the cyclic urethane ring moiety; (d) A is a substituted or unsubstituted, saturated or unsaturated, straight-chain or branched, C.sub.1 -C.sub.8 heteroalkyl; or a substituted or unsubstituted, saturated or unsaturated heterocycle having 6- or 7-members which may not have an oxygen atom; and A has one nitrogen atom which is adjacent to R.sub.4 ; and and the pharmaceutically-acceptable salts and esters thereof.

  本文所述的新型环状脲和其药用可接受的盐和酯，可用作抗心律失常和抗心颤药物，其具有以下一般结构：##STR1## 其中（a）X是饱和或不饱和的5、6或7元杂环或碳环；（b）Y是取代或未取代的、饱和或不饱和的5、6或7元杂环或碳环，或为零；（c）L选自烷基氨基，烯基氨基，烷基亚胺，烯基亚胺和酰胺的群，其中其氮原子与环状脲环基上的3位置的氮原子结合；（d）A是取代或未取代的、饱和或不饱和的直链或支链C.sub.1-C.sub.8杂原子烷基；或者是取代或未取代的、饱和或不饱和的6或7元杂环，可能没有氧原子；A具有一个氮原子，其邻近R.sub.4；以及其药用可接受的盐和酯。
• Oxazolidinone derivatives useful as antiarrhythmic and antifibrillatory agents
  申请人：Procter & Gamble Pharmaceuticals, Inc.

  公开号：EP0957103A1

  公开（公告）日：1999-11-17

  Cyclic urethane compounds which are useful as antiarrhythmic and antifibrillatory agents, and the pharmaceutically-acceptable salts and esters thereof, characterized in that they have the general structure: a) Y is an unsaturated, 5- membered heterocycle; b) R1, R2 and R3 are independently selected from hydrogen, Cl, F, Br, OH and CH3; c) R4 is C1-C8 alkyl; d) A is substituted or unsubstituted, saturated or unsaturated, straight-chain or branched C1-C8 heteroalkyl, and A has at least one nitrogen atom which is adjacent to R4.

  可用作抗心律失常和抗纤颤药物的环状氨基甲酸酯化合物及其药学上可接受的盐和酯，其特征在于它们具有一般结构： a) Y 是不饱和的 5 位杂环； b) R1、R2 和 R3 独立选自氢、Cl、F、Br、OH 和 CH3； c) R4 是 C1-C8 烷基； d) A 是取代或未取代的、饱和或不饱和的、直链或支链 C1-C8 杂烷基，且 A 具有至少一个与 R4 相邻的氮原子。
• Series of new nu-(5-nitro-2-furyl) alkylidene-3-amino-5-tertiaryamino-methyl-2-oxazolidones and the preparation thereof
  申请人：NORWICH PHARMA CO

  公开号：US02802002A1

  公开（公告）日：1957-08-06
• CYCLIC URETHANES USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS
  申请人：PROCTER & GAMBLE PHARMACEUTICALS

  公开号：EP0599968A1

  公开（公告）日：1994-06-08
• OXAZOLIDINONE DERIVATIVES USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS
  申请人：PROCTER & GAMBLE PHARMACEUTICALS, INC.

  公开号：EP0599968B1

  公开（公告）日：2000-01-12